UC San Francisco have developed a technique that turns face recognition tech on the problems raised by new drug development.The method uses algorithms akin to those used by face-recognition software alongside genetically modified cancer cells to develop early stage drugs.The cells, which will change their appearance when treated with drugs targeting common disease pathways, have been called ORACLs (Optimized Reporter cell lines for Annotating Compound Libraries).Earlier this week, UK-based firm Aurora revealed that it had been testing its deep learning engine for facial recognition on identifying cancerous cells.Using the dataset provided for the 2014 International Conference of Pattern Recognition challenge, the firm created an AI to detect the occurrence of mitosis. An analysis of the accuracy on a blind test set, demonstrated outstanding results and even suggest a higher level of accuracy that the 2014 competition winner.
Recent Articles
- Over 4,000 identity professionals now registered!
- Public trust must be restored if the UK government’s digital ID plans are to be saved
- Tech in Gov 2027: Solving government needs for digital public transformation
- Poland supports ban of “addictive” mobile phones
- Identity Week Europe 2026: IOM Sri Lanka to present comprehensive document verification solutions programme
Recent Video
- How interoperability of EES and ETIAS is designed to create a comprehensive view of traveller movement
- Ex Police detective Gavin Burton: Fraud prevention tools for police and border control
- Semperis: Operational resilience in Active Directory and Entra ID
- We’re back! The key features of Identity Week Europe 2026!
- How ICMPD is supporting Ukraine’s border resilience during crisis
